Market News & Trends
Starton Therapeutics Successfully Demonstrates Continuous Drug Delivery of Lenalidomide From a Transdermal Patch in an In Vivo Nonclinical Study With STAR-LLD
Starton Therapeutics Inc. recently announced it successfully obtained promising results in a non-GLP rabbit pharmacokinetic (PK) and skin irritation study of….
Soleno Therapeutics Provides Regulatory Update on DCCR for the Treatment of Prader-Willi Syndrome
Soleno Therapeutics, Inc. recently provided an update following recent interactions with the US FDA regarding the development of once-daily DCCR (diazoxide choline) extended-release tablets for….
Kura Oncology Receives FDA Authorization to Proceed With Phase 1b Study of KO-539 in Acute Myeloid Leukemia
Kura Oncology, Inc. recently announced the US FDA has lifted the partial clinical hold on the KOMET-001 Phase 1b study of KO-539 in patients with…
ASLAN Pharmaceuticals Initiates Phase 2b Study of ASLAN004 (Eblasakimab) in Moderate-to-Severe Atopic Dermatitis
ASLAN Pharmaceuticals recently announced it has screened the first patient in its Phase 2b dose-ranging clinical study of eblasakimab in adults with moderate-to-severe atopic dermatitis…
WuXi STA Launches its First Parenteral Formulation Manufacturing Line
WuXi STA recently announced its first parenteral formulation manufacturing line at the Wuxi city site is now in commission. This wholly automatic sterile manufacturing line operates…
Enteris BioPharma Launches Enhanced Website Showcasing Full Suite of Bench to Market™ Services
Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subsidiary of SWK Holdings Corporation (Nasdaq: SWKH), recently announced the launch….
Enteris BioPharma to Participate in Biotech Showcase Virtual & BIO Partnering at JPM During J.P. Morgan Week 2022
Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subsidiary of SWK Holdings Corporation, recently…
Zealand Pharma Completes Enrollment in EASE-SBS 1 Phase 3 Trial Assessing Glepaglutide in Patients With Short Bowel Syndrome
Zealand Pharma A/S recently announced completion of patient enrollment in its pivotal Phase 3 trial (EASE-SBS 1) of glepaglutide, the company’s long-acting GLP-2 analog, for…
First Patient Dosed in IntelGenx’s Resumed BUENA Montelukast VersaFilm Phase 2a Clinical Trial in Patients with Mild to Moderate Alzheimer’s Disease
IntelGenx Corp. recently announced patient dosing has resumed in the ongoing Phase 2a (BUENA) clinical trial in patients with mild to moderate Alzheimer’s Disease (AD)…
F-star Announces Issuance of US Patent Protecting FS118, a Bispecific Antibody Targeting PD-L1 & LAG-3
F-star Therapeutics, Inc. recently announced the USPTO has granted a patent protecting the composition of matter of FS118, F-star’s tetravalent bispecific antibody which blocks PD-L1 and LAG-3 receptors…..
BetterLife Receives FDA Response On Its Pre-IND Application For Major Depressive Disorder (MDD) Treatment With BETR-001
BetterLife Pharma Inc. recently announced it has received a written response from the US FDA to its pre-investigational new drug (pre-IND) application for the treatment…
Compass Therapeutics Announces US FDA Clearance of IND Application for Phase 2 Study of CTX-009, a Bispecific Antibody That Simultaneously Targets Delta-like Ligand 4 (DLL4) & Vascular Endothelial Growth Factor A (VEGF-A)
Compass Therapeutics, Inc. recently announced the US FDA has cleared its IND application for CTX-009, enabling the company to initiate a global Phase 2 clinical…
Spero Therapeutics Awarded up to an Additional $12.9 Million by BARDA to Support the Development of Orally Administered Tebipenem Pivoxil in Pediatric Patients
Spero Therapeutics, Inc. recently announced the company and the Biomedical Advanced Research and Development Authority (BARDA), part of the office of the Assistant Secretary for Preparedness and Response at the US….
Kinnate Biopharma Inc. Announces FDA Clearance of Investigational Drug Application for KIN-3248
Kinnate Biopharma Inc. recently announced the US FDA has cleared the company’s Investigational New Drug (IND) application for KIN-3248, a next-generation….
Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19
Revive Therapeutics Ltd. recently provided an update on the company’s US FDA Phase 3 clinical trial to evaluate the safety and efficacy of Bucillamine, an oral drug with….
VYNE Therapeutics Announces Phase 1b Data for FMX114 From Phase 1b/2a Trial for the Treatment of Mild-to-Moderate Atopic Dermatitis
VYNE Therapeutics Inc. recently announced it has completed the Phase 1b portion of a Phase 1b/2a clinical trial evaluating FMX114 for the treatment of mild-to-moderate…
Recce Pharmaceuticals Announces Positive Safety Data From Second Cohort of Phase 1 Clinical Trial Evaluating Healthy Subjects Intravenously Dosed With RECCE 327
Recce Pharmaceuticals Ltd recently reported further positive data from its Phase 1 intravenous (IV) clinical trial of RECCE 327 (R327), demonstrating safety and tolerability among…
ChemoCentryx Announces EU Approval of TAVNEOS for the Treatment of ANCA-Associated Vasculitis
ChemoCentryx, Inc. recently announced TAVNEOS (avacopan) has been approved within the European Union in combination with a rituximab or cyclophosphamide regimen for the treatment of…
Avomeen to Become Element
In early 2021 , Avomeen was acquired by Element Materials Technology, advancing Element’s commitment to providing best-in-class scientific solutions to the vital Life Sciences sector,…
Treadwell Therapeutics Engages Genezen to Advance its T cell Receptor-Based Cell Therapy Pipeline
Treadwell Therapeutics and Genezen have recently confirmed a partnership agreement to accelerate the production of T cell receptor (TCR)-based candidates to address unmet needs in cancer patients…..
